Skip to content
Clinical Trials – home
CzechiaBack to Czechia

Clinical trials in Nové Město na Moravě

2 clinical trials in Nové Město na Moravě, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Nové Město na Moravě at a glance
2
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Nové Město na Moravě

Open in trial search
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB

Embolism venous

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Sirius Therapeutics Inc.

Other cities in Czechia

The busiest research cities in the country

All 158 cities in Czechia

Clinical research in Nové Město na Moravě

What the registry says about research in the country

01 Nové Město na Moravě
Cardiovascular Diseases
Clinical research in Nové Město na Moravě is focused on cardiovascular‑related conditions, specifically exploring therapies for venous thromboembolism and renal outcomes in patients with Chronic kidney disease. Two actively recruiting trials aim to test a new anticoagulant and a novel metabolic agent. Evaluation of SRSD107 as a preventive anticoagulant after total knee arthroplasty. Assessment of elecoglipron’s ability to slow eGFR decline and lower mortality. Investigation of safety and tolerability in patients receiving background SGLT2 inhibitor therapy. Exploration of cardiovascular event rates in the studied populations. These studies, conducted at two local sites with dedicated investigators, aim to improve treatment options for cardiovascular patients and enhance long‑term kidney health.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.